Pfizer: positive phase 3 results in hemophilia A
(CercleFinance.com) - On Wednesday, Pfizer reported positive phase 3 results for its hemophilia A gene therapy developed jointly with Sangamo Therapeutics.
The company says that the trial met its primary endpoint by demonstrating superiority in terms of annual bleeding rate compared with factor VIII prophylaxis.
The biopharmaceutical group points out that these data were obtained from 12 weeks and for a period of at least 15 months after drug administration.
The aim of giroctocogene fitelparvovec - which is currently in the experimental stage - is to enable hemophilia A patients to produce FVIII themselves over a prolonged period from a single infusion, thereby reducing the need for routine prophylaxis via regular intravenous injections.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The company says that the trial met its primary endpoint by demonstrating superiority in terms of annual bleeding rate compared with factor VIII prophylaxis.
The biopharmaceutical group points out that these data were obtained from 12 weeks and for a period of at least 15 months after drug administration.
The aim of giroctocogene fitelparvovec - which is currently in the experimental stage - is to enable hemophilia A patients to produce FVIII themselves over a prolonged period from a single infusion, thereby reducing the need for routine prophylaxis via regular intravenous injections.
Copyright (c) 2024 CercleFinance.com. All rights reserved.